Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-Up of Prognostic Study Using Propensity Score Matching.
Oncology
; 100(5): 257-266, 2022.
Article
in En
| MEDLINE
| ID: mdl-35114682
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Neoadjuvant Therapy
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Oncology
Year:
2022
Document type:
Article
Affiliation country:
Japón
Country of publication:
Suiza